Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing